Real-World Treatment Patterns and Clinical Outcomes of BRAF V600-Mutant Metastatic Melanoma Patients Treated at Academic Oncology Centers in the United States

First published: 29/11/2024 Last updated: 29/11/2024





Administrative details

Study description

EU PAS number	
EUPAS1000000307	
Study ID	
100000307	
DARWIN EU® study	
No	
Study countries	
United States	

The overarching aim of this study is to describe the real-world characteristics, treatment patterns, and clinical outcomes of patients with BRAF V600-mutant MM presenting for care at academic oncology centers in the US from January 1, 2018 to June 30, 2024 (or the most recent date of data availability.

Study status

Planned

Research institutions and networks

Institutions

Pfizer

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Kristina Chen kristina.chen@pfizer.com

Study contact

kristina.chen@pfizer.com

Primary lead investigator

Kristina Chen

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 04/04/2023

Study start date

Planned: 18/11/2024

Data analysis start date

Planned: 06/12/2024

Date of final study report

Planned: 20/06/2025

Sources of funding

Pharmaceutical company and other private sector

Study protocol

C4221039_RW Treatment Patterns and Clinical Outcomes in BRAF+ MM_Study Protocol V1.0 17Oct2024 REDACTED.pdf (1.72 MB)

Regulatory

Was the study required by a regulatory body?

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Data collection methods:

Secondary use of data

Study design:

A non-interventional (NI) longitudinal cohort design will be employed for this study.

Deidentified patient data collected retrospectively from academic oncology centers will be used to address all study objectives.

Study Design

Non-interventional study design

Cohort

Population studied

Age groups

• Adult and elderly population (≥18 years)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No